Tobira Therapeutics Inc. (TBRA) announced Monday morning that its Phase 2b clinical trial of cenicriviroc, for the treatment of NASH in 289 adults with liver fibrosis, did not meet its primary endpoint of a two-point reduction in the NAFLD Activity Score.
from RTT - Before the Bell http://ift.tt/2abzQ9G
via IFTTT
No comments:
Post a Comment